Cell-free nucleic acids as biomarkers in cancer patients

By H. Schwarzenbach, D. Hoon, K. Pantel. Nature Reviews. Cancer, 2011

2,804 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/39dab331e1c5632f4115a3c409e49f7a22f43970

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. C. Alix‐Panabières
2. K. Pantel
3. J. Reis-Filho
4. Jay Shendure

In Molecular Biology

1. C. Alix‐Panabières
2. K. Pantel
3. J. Kitzman
4. J. Reis-Filho
5. Ming-Sound Tsao
6. Shifu Chen
7. Yasushi Yatabe
8. Jay Shendure

Citations in the corpus

• Circulating tumor cells: liquid biopsy of cancer. (2013, background): “In addition, there is still a great interest in studying cell-free tumor DNA in parallel with CTCs (44, 45).”
• MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review (2012, neutral): “…be reliably extracted and detected from frozen and paraffin-embedded tissues, from blood (either total blood, plasma or serum; Mitchell et al, 2008; Schwarzenbach et al, 2011), circulating exosomes (Taylor & Gercel-Taylor, 2008), and from different biologic fluids like urine (Hanke et al, 2010),…”
• Fragment Length of Circulating Tumor DNA (2016, background): “Increased quantity of cell-free DNA in the circulation has been associated with malignant solid tumors [1].”
• Tumor Metastasis: Molecular Insights and Evolving Paradigms (2011, neutral): “…platforms, as well as, perhaps, direct detection of tumor-specific molecular alterations in freely circulating nucleic acids present in the bloodstream (Schwarzenbach et al., 2011), may come to represent important clinical tools for diagnosing and guiding the treatment of metastatic disease.”
• ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. (2022, background): “7 The release of plasma DNA preferentially occurs as a result of cell death, apoptosis and necrosis, however other biological processes may contribute.”
• Comparing the MicroRNA Spectrum between Serum and Plasma (2012, background): “These findings raise the possibility of using the levels of specific miRNAs in circulation as biomarkers for different pathological conditions [8–12].”